Cofertility vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cofertility matches women who want to freeze eggs for their future with intended parents who need donor eggs, reducing the cost of freezing by sharing eggs with recipients.
About
Cofertility is a fertility technology company founded in 2021 that has created a unique egg sharing model connecting women who want to freeze their eggs with intended parents who need donor eggs. Through the platform's Split program, egg donors freeze half of their eggs for their own future use while the other half goes to recipients, with the recipient paying for the donor's entire egg freezing cycle. This arrangement makes egg freezing free for donors who would otherwise pay $10,000 or more out of pocket, while providing recipients with a younger, more diverse egg donor pool. Cofertility raised $30M and has built the largest technology-first egg donation platform, emphasizing donor safety, informed consent, and transparent compensation practices that differ from traditional egg donation agencies. The company screens donors and handles all clinical coordination with partner fertility clinics. Cofertility addresses both the financial barrier to egg freezing that prevents many women from accessing this preventive care and the limited supply of diverse egg donors that many intended parents face. The platform represents a novel market structure that creates value for donors, recipients, and the overall fertility ecosystem simultaneously.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.